Autologous Stem Cell Gene Therapy Market Global Report 2026

The autologous stem cell gene therapy market size has grown exponentially in recent years. It will grow from $2.82 billion in 2025 to $3.48 billion in 2026 at a compound annual growth rate (CAGR) of 23.4%. The growth in the historic period can be attributed to growing prevalence of rare genetic disorders, increasing investment in regenerative medicine research, expansion of stem cell therapy clinical studies, rising demand for targeted treatment approaches, growing support for advanced therapeutic development.

The autologous stem cell gene therapy market size is expected to see exponential growth in the next few years. It will grow to $7.97 billion in 2030 at a compound annual growth rate (CAGR) of 23.0%. The growth in the forecast period can be attributed to increasing commercialization of personalized gene therapies, rising adoption of advanced gene editing technologies, growing investments in cell and gene therapy manufacturing facilities, increasing focus on curative treatment development, expansion of clinical pipeline activities for genetic diseases. Major trends in the forecast period include increasing adoption of personalized regenerative therapies, expansion of targeted stem cell modification approaches, growing use of patient-specific treatment strategies, increasing focus on curative therapies for rare diseases, advancement in ex vivo cellular engineering techniques.

The increasing demand for personalized medicine is expected to drive the growth of the autologous stem cell gene therapy market going forward. Personalized medicine is a healthcare approach that utilizes an individual’s genetic and biological information to develop more targeted and effective treatments rather than relying on conventional one-size-fits-all therapies. The adoption of personalized medicine is rising due to advancements in genomic sequencing technologies, which enable faster and more affordable analysis of individual genetic profiles, supporting accurate diagnosis and targeted treatment selection. Autologous stem cell gene therapy advances personalized medicine by utilizing a patient’s own stem cells, which are genetically modified and reintroduced into the body, allowing treatments to be specifically designed for the patient’s genetic condition, improving treatment compatibility, and lowering the risk of immune rejection. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 new personalized treatments for rare disease patients in 2023, compared with six in 2022, including newly approved personalized therapies introduced during 2023. Therefore, the increasing demand for personalized medicine is driving the growth of the autologous stem cell gene therapy market.

Major companies operating in the autologous stem cell gene therapy market are focusing on developing advanced solutions, such as gene therapy treatments, to facilitate precise patient-specific genetic correction and tissue regeneration for enhanced therapeutic outcomes. Gene therapy is a medical treatment approach that involves modifying, replacing, or introducing genetic material into a patient’s cells to prevent, treat, or potentially cure diseases. For instance, in December 2025, Fondazione Telethon ETS, an Italy-based nonprofit biomedical foundation, received approval from the Food and Drug Administration (FDA) for Waskyra (etuvetidigene autotemcel), the first gene therapy treatment for Wiskott-Aldrich syndrome (WAS), representing a significant advancement for patients without a suitable matched stem cell donor. The treatment is an ex vivo, autologous hematopoietic stem cell gene therapy that uses the patient’s own CD34+ hematopoietic stem and progenitor cells, which are collected, genetically modified using a lentiviral vector containing a functional WAS gene, and subsequently reinfused into the patient.

In June 2025, Carlyle Group and SK Capital Partners, a US-based investment company, acquired Bluebird Bio Inc. for $29 billion. Through this acquisition, Carlyle Group and SK Capital seek to enhance Bluebird Bio’s commercialization efforts and financial stability to accelerate the development and global commercialization of its gene therapy treatments. Bluebird Bio Inc. is a US-based biotechnology company that provides autologous stem cell gene therapy.

Major companies operating in the autologous stem cell gene therapy market report are Johnson & Johnson, Novartis AG, Bristol Myers Squibb Company, Vertex Pharmaceuticals Incorporated, Lonza Group AG, BioNTech SE, Kite Pharma Inc., CRISPR Therapeutics AG, Beam Therapeutics Inc., Sangamo Therapeutics Inc., Minaris Regenerative Medicine GmbH, Editas Medicine Inc., Intellia Therapeutics Inc., Caribou Biosciences Inc., Autolus Therapeutics plc, Rocket Pharmaceuticals Inc., JW Therapeutics Co. Ltd., CARsgen Therapeutics Holdings Limited, bluebird bio Inc., Orchard Therapeutics, CSL Behring, Genethon, Mesoblast Limited.

North America was the dominating region in the autologous stem cell gene therapy market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the autologous stem cell gene therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the autologous stem cell gene therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.